Emerald trial gleams for Morphic

Safe, effective and oral. That is the centre of the Venn diagram that no ulcerative colitis therapy has yet managed to occupy, but data reported today suggest that Morphic Therapeutic’s α4β7 inhibitor MORF-057 might be the first to get there. The project’s potential as a future first-line therapy caused the group’s stock to pop 13%.